{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreigvflnuyltbpylbdatnvbqphasbiue3hquvduumxa2jgiczb5d2u4",
    "uri": "at://did:plc:pmmp7irwts7faw56jdxk3idc/app.bsky.feed.post/3mellso5pu6a2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreih4jmehi7bxjjd74vcgmugo6lriozfshzlnfgvp4zcrjkfwievhha"
    },
    "mimeType": "image/jpeg",
    "size": 708472
  },
  "path": "/news/2026-02-immune-markers-months-longer-survival.html",
  "publishedAt": "2026-02-11T07:30:01.000Z",
  "site": "https://medicalxpress.com",
  "tags": [
    "Oncology & Cancer"
  ],
  "textContent": "Researchers at The University of Texas MD Anderson Cancer Center have identified blood-based biomarkers that can help distinguish patients with glioblastoma who are most likely to live longer from novel treatment with an engineered oncolytic virus, Delta-24-RGD, that targets and eliminates cancer cells.",
  "title": "Study finds immune markers at two months tied to longer survival in glioblastoma trial"
}